



Charles M Beasley Jr  
11/10/99 03:48 PM

To: Norma Kim Ascroft/AM/LLY@Lilly, Anna Thornton/AM/LLY@Lilly  
cc: John A Krueger/AM/LLY@Lilly  
Subject: Executive Steering Committee for Olanzapine-associated Weight Changes and Hyperglycemia

Anna:

Please forward my summary of the post-marketing hyperglycemia data to Norma, she may want to convert it to slide format.

Charles

----- Forwarded by Charles M Beasley Jr/AM/LLY on 11/10/99 03:43 PM -----



Norma Kim Ascroft  
11/10/99 12:10 PM

To: Charles M Beasley Jr/AM/LLY@Lilly, Jamie Dananberg/AM/LLY@Lilly, Lawrence Gelbert/AM/LLY@Lilly, Mark L Heiman/AM/LLY@Lilly, J David Leander/AM/LLY@Lilly  
cc: Norma Kim Ascroft/AM/LLY@Lilly  
Subject: Executive Steering Committee for Olanzapine-associated Weight Changes and Hyperglycemia

In preparation of the Steering committee meeting on the 23rd, it would be greatly appreciated to forward electronically your 2-4 slides that will be utilized in the overviews to Barbara Whitaker, Sr Asst to Alan Breier (please cc; Norma Ascroft), by November 17, 1999. The acetates will be collated and ready for the presentation on the 23rd.

Thank you and we look forward to seeing you on the 23rd.

----- Forwarded by Norma Kim Ascroft/AM/LLY on 11/10/99 12:04 PM -----



**Alan Breier**  
11/09/99 05:03 PM

\*\*\*\*\*

To: Charles M Beasley Jr/AM/LLY@Lilly, Thomas F Bumol/AM/LLY@Lilly, Frank Bymaster/AM/LLY@Lilly, Jose F Caro/AM/LLY@Lilly, Jamie Dananberg/AM/LLY@Lilly, Richard D DiMarchi/AM/LLY@Lilly, H Christian Fibiger/AM/LLY@Lilly, Dong-Jing Fu/AM/LLY@Lilly, Lawrence Gelbert/AM/LLY@Lilly, Brian Grinnell/AM/LLY@Lilly, Mark L Heiman/AM/LLY@Lilly, Richard Deane Hockett/AM/LLY@Lilly, J David Leander/AM/LLY@Lilly, Karena Meehan/AM/LLY@Lilly, Edmundo Muniz/AM/LLY@Lilly, Steven M Paul/AM/LLY@Lilly, Gregory S Probst/AM/LLY@Lilly, Eric Ravussin/AM/LLY@Lilly, Paul R Rosteck Jr/AM/LLY@Lilly, Gary D Tollefson/AM/LLY@Lilly, Louis Vignati/AM/LLY@Lilly  
cc: Norma Kim Ascroft/AM/LLY@Lilly, Alan Breier/AM/LLY@Lilly, John C Lechleiter/AM/LLY@Lilly, August M Watanabe/AM/LLY@Lilly  
Subject: Executive Steering Committee for Olanzapine-associated Weight Changes and Hyperglycemia

Olanzapine-associated weight gain and possible hyperglycemia is a major threat to the long-term success of this critically important molecule. In addition, it could be argued that Eli Lilly, with its strengths in neuroscience, metabolism, endocrinology and diabetology is better positioned than any other institution to elucidate the mechanisms and developed treatments for this side effect. Thus,

ZY 1972 1720

we have formed a cross-functional action team to meet these challenges. Success of this effort will contribute to securing the future of olanzapine and the financial health of our company, and likely spur the development of next generation antipsychotic drugs (i.e. olanzapine without the weight gain) and drugs for obesity.

A pivotal meeting of the Olanzapine-Associated Weight Changes and Hyperglycemia Cross-Functional Action Team has been placed on your calendars for **Tuesday, November 23, 1999, 3:00 PM to 5:00 PM**. The purpose of this meeting is for the Executive Steering Committee, comprised of Alan Breier, Jose Caro, Richard DiMarchi, Chris Fibiger, Steve Paul, Greg Probst and Gary Tollefson, to review the ongoing work, future study plans and resource needs and provide guidance for the scope and direction for future activities. The format of the meeting will be 1:15 minutes of presentations followed by a 45 minute closed meeting of the Steering Committee. The agenda is attached.

I want to thank you in advance for joining us to work on this important project and look forward to seeing you on the 23rd.



Alan

agendaNov23Mtg.doc

ZY 1972 1721